tetano
Editor, Senior Moderator
PLoS Pathog
. 2021 Mar 25;17(3):e1009383.
doi: 10.1371/journal.ppat.1009383. Online ahead of print.
Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model
Drishya Kurup[SUP] 1 [/SUP], Delphine C Malherbe[SUP] 2 3 [/SUP], Christoph Wirblich[SUP] 1 [/SUP], Rachael Lambert[SUP] 1 [/SUP], Adam J Ronk[SUP] 2 3 [/SUP], Leila Zabihi Diba[SUP] 1 [/SUP], Alexander Bukreyev[SUP] 2 3 4 [/SUP], Matthias J Schnell[SUP] 1 5 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.
. 2021 Mar 25;17(3):e1009383.
doi: 10.1371/journal.ppat.1009383. Online ahead of print.
Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model
Drishya Kurup[SUP] 1 [/SUP], Delphine C Malherbe[SUP] 2 3 [/SUP], Christoph Wirblich[SUP] 1 [/SUP], Rachael Lambert[SUP] 1 [/SUP], Adam J Ronk[SUP] 2 3 [/SUP], Leila Zabihi Diba[SUP] 1 [/SUP], Alexander Bukreyev[SUP] 2 3 4 [/SUP], Matthias J Schnell[SUP] 1 5 [/SUP]
Affiliations
- PMID: 33765062
- DOI: 10.1371/journal.ppat.1009383
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.